phenylethanolamine

Phenylethanolamine
Names
	IUPAC name 2-Amino-1-phenylethanol
Identifiers
CAS Number	7568-93-6
ChEBI	CHEBI:16343
ChEMBL	ChEMBL19216
ChemSpider	975
Jmol 3D model	Interactive image
KEGG	C02735
PubChem	1000
	InChI InChI=1S/C8H11NO/c9-6-8(10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2 Key: ULSIYEODSMZIPX-UHFFFAOYSA-N ; InChI=1/C8H11NO/c9-6-8(10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2 Key: ULSIYEODSMZIPX-UHFFFAOYAE ;
	SMILES OC(c1ccccc1)CN ;
Properties
Chemical formula	C8H11NO
Molar mass	137.18 g/mol
Appearance	pale yellow solid
Melting point	56 to 57 °C (133 to 135 °F; 329 to 330 K)
Boiling point	157 to 160 °C (315 to 320 °F; 430 to 433 K) at 17 mmHg
Solubility in water	soluble
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

フェニルエタノールアミン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/09/05 18:54:09」(JST)

wiki en

[Wiki en表示]

Phenylethanolamine (sometimes abbreviated PEOH), or β-hydroxyphenethylamine, is a trace amine with a structure similar to those of other trace phenethylamines as well as the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. As an organic compound, phenylethanolamine is a β-hydroxylated phenethylamine that is also structurally related to a number of synthetic drugs in the substituted phenethylamine class. In common with these compounds, phenylethanolamine has strong cardiovascular activity^[1] and, under the name Apophedrin, has been used as a drug to produce topical vasoconstriction.^[2]

In appearance, phenylethanolamine is a white solid.

Phenylethanolamine is perhaps best known in the field of bioscience as part of the enzyme name "phenylethanolamine N-methyl transferase", referring to an enzyme which is responsible for the conversion of norepinephrine into epinephrine, as well as other related transformations.^[3]

Occurrence

Phenylethanolamine has been found to occur naturally in several animal species, including humans.^[4]^[5]

Chemistry

Synthesis

An early synthesis of phenylethanolamine was by the reduction of 2-nitro-1-phenyl-ethanol.^[6] Other early syntheses are summarized in a paper by Hartung and Munch.^[7]

A more recent synthesis, providing a better yield, is by the reduction of benzoyl cyanide using LiAlH₄.^[8]

Properties

Chemically, phenyethanolamine is an aromatic compound, an amine, and an alcohol. The amino-group makes this compound a weak base, capable of reacting with acids to form salts.

Two common salts of phenylethanolamine are the hydrochloride, C₈H₁₁NO.HCl, m.p. 212 °C,^[6] and the sulfate, (C₈H₁₁NO)₂.H₂SO₄, m.p. 239–240 °C.^[2]^[9]

The pK_a of phenylethanolamine hydrochloride, at 25 °C and at a concentration of 10mM, has been recorded as 8.90.^[10]

The presence of the hydroxy-group on the benzylic carbon of the phenylethanolamine molecule creates a chiral center, so the compound exists in the form of two enantiomers, d- and l-phenylethanolamine, or as the racemic mixture, d,l-phenylethanolamine. The dextrorotatory isomer^[11] corresponds to the S-configuration, and the levorotatory isomer^[12] to the R-configuration^[13] The data given at right is for the racemate.

The synthesis of (S)-(+)-phenylethanolamine, from (+)-mandelic acid, via (+)-mandelamide, has been described.^[14] The physical constants reported in this paper are as follows: m.p. 55–57 °C; [α] = + 47.9° (c 2.4, in ethanol).

Pharmacology

Early, classical pharmacological studies of phenylethanolamine were carried out by Tainter, who observed its effects after administering it to rabbits, cats and dogs. The drug produced a rapid rise in blood pressure when administered intravenously, but had little or no effect when given by any other route: doses as high as 200 mg given subcutaneously to rabbits did not alter blood pressure, nor were there any effects when the drug was intubated into the stomach.

In man, a total oral dose of 1 g also produced no effects.

Doses of 1–5 mg/kg, intravenously, caused no definite changes in respiration in cats or rabbits, and additional experiments showed that phenylethanolamine had no broncho-dilatory properties in animals. There was a similar lack of effect when the drug was given subcutaneously to man.

In vivo and in vitro experiments involving cat and rabbit intestinal smooth muscle showed that the drug produced relaxation and inhibition.

A detailed examination of the mydriatic effect of phenylethanolamine led Tainter to conclude that this drug acted by direct stimulation of the radial dilator muscle in the eye.^[9]

Shannon and co-workers confirmed and extended some of Tainter's studies. After administering phenylethanolamine to dogs intravenously, these investigators observed that 10–30 mg/kg of the drug increased pupil diameter, and decreased body temperature; a dose of 10 or 17.5 mg/kg decreased heart rate, but a 30 mg/kg dose caused it to increase. Other effects that were noted included profuse salivation and piloerection. Phenylethanolamine also produced behavioral effects such as stereotyped head movement, rapid eye movement, and repetitive tongue extrusion. These and other observations were suggested to be consistent with an action on α- and β-adrenergic receptors.^[15]

Research by Carpéné and co-workers showed that phenylethanolamine^[16] did not significantly stimulate lipolysis in cultured adipocytes ("fat cells") from guinea pig or human. Moderate stimulation (intrinsic activities about half that of the reference standard, isoprenaline) was observed in adipocytes from rat or hamster. This lipolysis was inhibited completely by bupranolol (considered to be a non-selective β-blocker), CGP 20712A (considered to be a selective β₁-antagonist), and ICI 118,551 (considered to be a selective β₂-antagonist), but not by SR 59230A (considered to be a selective β₃-antagonist).^[17]

Using a β₂ adrenergic receptor preparation derived from transfected HEK 293 cells, Liappakis and co-workers^[18] found that in wild-type receptors, racemic phenylethanolamine^[19] had ~ 1/400 x the affinity of epinephrine, and ~ 1/7 x the affinity of norepinephrine in competition experiments with ³[H]-CGP-12177.^[20]

The two enantiomers of phenylethanolamine were studied for their interaction with the human trace amine associated receptor (TAAR1) by a research group at Eli Lilly. From experiments with human TAAR1 expressed in rGα_sAV12-664 cells, Wainscott and co-workers observed that R-(−)-phenylethanolamine (referred to as "R-(−)-β-hydroxy-β-phenylethylamine") had an ED₅₀ of ~1800 nM, with an E_max of ~ 110%, whereas S-(+)-phenylethanolamine (referred to as "S-(+)-β-hydroxy-β-phenylethylamine") had an ED₅₀ of ~1720 nM, with an E_max of ~ 105%. In comparison, β-phenethylamine itself had an ED₅₀ of ~106 nM, with an E_max of ~ 100%.^[21] In other words, phenylethanolamine is a TAAR1 agonist and trace amine.^[21]

Pharmacokinetics

The pharmacokinetics of phenylethanolamine, after intravenous administration to dogs, were studied by Shannon and co-workers, who found that the drug followed the "two-compartment model", with T_1/2(α) ≃ 6.8 mins and T_1/2(β) ≃ 34.2 mins; the "plasma half-life" of phenylethanolamine was therefore about 30 minutes.^[15]

Biochemistry

Phenylethanolamine was found to be an excellent substrate for the enzyme phenylethanolamine N-methyl transferase (PNMT), first isolated from monkey adrenal glands by Julius Axelrod, which transformed it into N-methylphenylethanolamine.^[22]

Subsequent studies by Rafferty and co-workers showed that substrate specificity of PNMT from bovine adrenal glands for the different enantiomers of phenylethanolamine was in the order R-(−)-PEOH > R,S-(racemic)-PEOH > S-(+)-PEOH.^[13]

Toxicology

The minimum lethal dose (m.l.d.) upon subcutaneous administration to guinea pigs was ~ 1000 mg/kg; the m.l.d. upon intravenous administration to rabbits was 25–30 mg/kg.;^[6] in rats, the m.l.d. after intravenous administration was 140 mg/kg.^[9]

References

^ W. H. Hartung (1945). "Beta-phenethylamine derivatives." Ind. Eng. Chem. 37 126–136.
^ ^a ^b The Merck Index, 10th Ed. (1983), p. 1051, Merck & Co., Rahway.
^ J. Axelrod (1966). "Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol. Rev. 18 95–113.
^ E. E. Inwang, A. D. Mosnaim and H. C. Sabelli (1973). "Isolation and characterization of phenethylamine and phenylethanolamine from human brain." J. Neurochem. 20 1469–1473.
^ H. E. Shannon and C. M. Degregorio (1982). "Self-administration of the endogenous trace amines beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs." J. Pharmacol. Exp. Ther. 222 52–60.
^ ^a ^b ^c G. A. Alles (1927). "The comparative physiological action of phenylethanolamine." J. Pharmacol. Exp. Ther. 32 121–133.
^ W. H. Hartung and J. C. Munch (1929). "Amino alcohols. I. Phenylpropanolamine and para-tolylpropanolamine." J. Am. Chem. Soc. 51 2262–2266.
^ A. Burger and E. D. Hornbacker (1952). "Reduction of acyl cyanides with lithium aluminum hydride." J. Am. Chem. Soc. 74 5514.
^ ^a ^b ^c M. L. Tainter (1929). "Pharmacological actions of phenylethanolamine." J. Pharmacol. Exp. Ther. 36 29–54.
^ J. Armstrong and R. B. Barlow (1976). "The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants." Br. J. Pharmacol. 57 501–516.
^ CAS # 56613-81-1
^ CAS # 2549-14-6
^ ^a ^b M. F. Rafferty , D. S. Wilson , J. A. Monn , P. Krass , R. T. Borchardt , and G. L. Grunewald (1982). "Importance of the aromatic ring in adrenergic amines. 7. Comparison of the stereoselectivity of norepinephrine N-methyltransferase for aromatics. Nonaromatic substrates and inhibitors." J. Med. Chem. 25 1198–1204.
^ A. I. Meyers and J. Slade (1980). "Asymmetric addition of organometallics to chiral ketooxazolines. Preparation of enantiomerically enriched α-hydroxy acids." J. Org. Chem. 45 2785–2791.
^ ^a ^b H. E. Shannon, E. J. Cone and D. Yousefnejad (1981). "Physiologic effects and plasma kinetics of phenylethanolamine and its N-methyl homolog in the dog." J. Pharmacol. Exp. Ther. 217 379–385.
^ The drug was tested in the form of a racemic mixture.
^ C. Carpéné, J. Galitzky, E. Fontana, C. Atgié, M. Lafontan and M. Berlan(1999). "Selective activation of β₃- adrenoceptors by octopamine: comparative studies in mammalian fat cells." Naunyn-Schmiedebergs Arch. Pharmacol. 359 310–321.
^ G. Liapakis, W. C. Chan, M. Papadokostaki and J. A. Javitch (2004). "Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β₂ adrenergic receptor." Mol. Pharmacol. 65 1181–1190.
^ Named imprecisely as "hydroxyphenethylamine"
^ Considered to be an antagonist of β₁ and β₂ receptors, and an agonist of β₃ receptors.
^ ^a ^b Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, Nelson DL (January 2007). "Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 475–485. doi:10.1124/jpet.106.112532. PMID 17038507. Substitution on the ethylamine side chain produced a variety of effects on potency at the human TAAR1, depending on the nature of the substituent. For example, a β-methyl substituent was well tolerated, being as potent as β-PEA itself (Table 3). However, changing that substitution to a β-hydroxy resulted in a 10-fold reduction in potency ...
"Table 3"
^ J.Axelrod (1962). "Purification and properties of phenylethanolamine-N-methyl transferase." J. Biol. Chem. 237 1657–1660.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 副腎の外科解剖学 surgical anatomy of the adrenal glands
2. 副腎不全の稀な原因 unusual causes of adrenal insufficiency
3. 神経系および行動に及ぼすステロイドの作用 glucocorticoid effects on the nervous system and behavior
4. 遺伝的疾患における褐色細胞腫 pheochromocytoma in genetic disorders
5. 肝性脳症：病因 hepatic encephalopathy pathogenesis

English Journal

Broad screening and identification of β-agonists in feed and animal body fluid and tissues using ultra-high performance liquid chromatography-quadrupole-orbitrap high resolution mass spectrometry combined with spectra library search.

Li T1, Cao J2, Li Z2, Wang X1, He P3.
Food chemistry.Food Chem.2016 Feb 1;192:188-96. doi: 10.1016/j.foodchem.2015.06.104. Epub 2015 Jun 30.
Broad screening and identification of β-agonists in feed, serum, urine, muscle and liver samples was achieved in a quick and highly sensitive manner using ultra high performance liquid chromatography-quadrupole-orbitrap high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) combined with a spect
PMID 26304337

Sensitive detection of β-agonists in pork tissue with novel molecularly imprinted polymer extraction followed liquid chromatography coupled tandem mass spectrometry detection.

Wang P1, Liu X2, Su X3, Zhu R4.
Food chemistry.Food Chem.2015 Oct 1;184:72-9. doi: 10.1016/j.foodchem.2015.03.073. Epub 2015 Mar 26.
A novel molecularly imprinted polymer micro-spheres (MIPMs) with phenylethanolamine A as the template and the p-vinylbenzoic acid as the functional monomer were synthesized for the selective absorption of clenbuterol and other β-agonists including brombuterol, bromchlorbuterol, clorprenaline and ra
PMID 25872428

Rapid determination of phenylethanolamine A in biological samples by enzyme-linked immunosorbent assay and lateral-flow immunoassay.

Li X1, Wang W, Wang L, Wang Q, Pei X, Jiang H.
Analytical and bioanalytical chemistry.Anal Bioanal Chem.2015 Aug 9. [Epub ahead of print]
Phenylethanolamine A (PA) is a β-adrenergic agonist, which was first used in animal husbandry as a growth promoter in China in 2010. In this study, a monoclonal-antibody (mAb)-based indirect competitive enzyme-linked immunosorbent assay (icELISA) and lateral-flow immunoassay (LFA) for the detectio
PMID 26255292

Japanese Journal

Low-Intensity Aerobic Exercise Mitigates Exercise-Induced Bronchoconstriction by Improving the Function of Adrenal Medullary Chromaffin Cells in Asthmatic Rats

The Tohoku Journal of Experimental Medicine 234(2), 99-110, 2014
NAID 130004687564

Synthesis and Evaluation of Novel Phenylethanolamine Derivatives containing Acetanilides as Potent and Selective .BETA.3-Adrenergic Receptor Agonists

Chemical and Pharmaceutical Bulletin 58(4), 533-545, 2010
NAID 130000255952

酵素関係(アイソザイムを含む) フェニルエタノラミンN-メチルトランスフェラーゼ (広範囲血液・尿化学検査,免疫学的検査(第7版・1)その数値をどう読むか) -- (生化学的検査(1))

日本臨床 67(-), 501-504, 2009-12
NAID 40016874541

Related Pictures

[1] W. H. Hartung (1945). "Beta-phenethylamine derivatives." Ind. Eng. Chem. 37 126–136.

[Mer-2] The Merck Index, 10th Ed. (1983), p. 1051, Merck & Co., Rahway.

[3] J. Axelrod (1966). "Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol. Rev. 18 95–113.

[4] E. E. Inwang, A. D. Mosnaim and H. C. Sabelli (1973). "Isolation and characterization of phenethylamine and phenylethanolamine from human brain." J. Neurochem. 20 1469–1473.

[5] H. E. Shannon and C. M. Degregorio (1982). "Self-administration of the endogenous trace amines beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs." J. Pharmacol. Exp. Ther. 222 52–60.

[All-6] G. A. Alles (1927). "The comparative physiological action of phenylethanolamine." J. Pharmacol. Exp. Ther. 32 121–133.

[7] W. H. Hartung and J. C. Munch (1929). "Amino alcohols. I. Phenylpropanolamine and para-tolylpropanolamine." J. Am. Chem. Soc. 51 2262–2266.

[8] A. Burger and E. D. Hornbacker (1952). "Reduction of acyl cyanides with lithium aluminum hydride." J. Am. Chem. Soc. 74 5514.

[Tain-9] M. L. Tainter (1929). "Pharmacological actions of phenylethanolamine." J. Pharmacol. Exp. Ther. 36 29–54.

[10] J. Armstrong and R. B. Barlow (1976). "The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants." Br. J. Pharmacol. 57 501–516.

[11] CAS # 56613-81-1

[12] CAS # 2549-14-6

[Raf-13] M. F. Rafferty , D. S. Wilson , J. A. Monn , P. Krass , R. T. Borchardt , and G. L. Grunewald (1982). "Importance of the aromatic ring in adrenergic amines. 7. Comparison of the stereoselectivity of norepinephrine N-methyltransferase for aromatics. Nonaromatic substrates and inhibitors." J. Med. Chem. 25 1198–1204.

[14] A. I. Meyers and J. Slade (1980). "Asymmetric addition of organometallics to chiral ketooxazolines. Preparation of enantiomerically enriched α-hydroxy acids." J. Org. Chem. 45 2785–2791.

[Shan-15] H. E. Shannon, E. J. Cone and D. Yousefnejad (1981). "Physiologic effects and plasma kinetics of phenylethanolamine and its N-methyl homolog in the dog." J. Pharmacol. Exp. Ther. 217 379–385.

[16] The drug was tested in the form of a racemic mixture.

[17] C. Carpéné, J. Galitzky, E. Fontana, C. Atgié, M. Lafontan and M. Berlan(1999). "Selective activation of β₃- adrenoceptors by octopamine: comparative studies in mammalian fat cells." Naunyn-Schmiedebergs Arch. Pharmacol. 359 310–321.

[18] G. Liapakis, W. C. Chan, M. Papadokostaki and J. A. Javitch (2004). "Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the β₂ adrenergic receptor." Mol. Pharmacol. 65 1181–1190.

[19] Named imprecisely as "hydroxyphenethylamine"

[20] Considered to be an antagonist of β₁ and β₂ receptors, and an agonist of β₃ receptors.

[TAAR1_ligands-21] Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, Nelson DL (January 2007). "Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 475–485. doi:10.1124/jpet.106.112532. PMID 17038507. Substitution on the ethylamine side chain produced a variety of effects on potency at the human TAAR1, depending on the nature of the substituent. For example, a β-methyl substituent was well tolerated, being as potent as β-PEA itself (Table 3). However, changing that substitution to a β-hydroxy resulted in a 10-fold reduction in potency ...
"Table 3"

[22] J.Axelrod (1962). "Purification and properties of phenylethanolamine-N-methyl transferase." J. Biol. Chem. 237 1657–1660.

v t e Phenethylamines

Phenethylamines	Psychedelics: 25B-NBOMe 25C-NBOMe 25D-NBOMe 25I-NBOMe 25N-NBOMe 2C-B 2C-B-AN 2C-B-FLY βk-2C-B 2C-C 2C-D 2C-E 2C-EF 2C-F 2C-G 2C-I 2C-N 2C-P 2C-SE 2C-T 2C-T-2 2C-T-4 2C-T-7 2C-T-8 2C-T-9 2C-T-13 2C-T-15 2C-T-16 2C-T-17 2C-T-21 2C-TFM 2C-YN Allylescaline DESOXY Escaline Isoproscaline Jimscaline Macromerine MEPEA Mescaline Metaescaline Methallylescaline Proscaline Psi-2C-T-4 TCB-2 Stimulants: Phenylethanolamine Hordenine Phenethylamine α-Methylphenethylamine (amphetamine) β-Methylphenethylamine m-Methylphenethylamine N-Methylphenethylamine o-Methylphenethylamine p-Methylphenethylamine Entactogens: Lophophine MDPEA MDMPEA Others: BOH DMPEA

Amphetamines	Psychedelics: 3C-BZ 3C-E 3C-P Aleph Beatrice Bromo-DragonFLY D-Deprenyl DMA DMCPA DMMDA DOB DOC DOEF DOET DOI DOM DON DOPR DOTFM Ganesha MMDA MMDA-2 Psi-DOM TMA TeMA Stimulants: 2-FA 2-FMA 3-FA 3-FMA Acridorex Alfetamine Amfecloral Amfepentorex Amphetamine (Dextroamphetamine, Levoamphetamine) Amphetaminil Benfluorex Benzphetamine Cathine Clobenzorex Dimethylamphetamine Ephedrine Etilamfetamine Fencamfamine Fencamine Fenethylline Fenfluramine (Dexfenfluramine, Levofenfluramine) Fenproporex Flucetorex Fludorex Formetorex Furfenorex Gepefrine 4-Hydroxyamphetamine Iofetamine Isopropylamphetamine Lefetamine Lisdexamfetamine Mefenorex Metaraminol Methamphetamine (Dextromethamphetamine, Levomethamphetamine) Methoxyphenamine MMA Morforex Norfenfluramine L -Norpseudoephedrine N,alpha-Diethylphenylethylamine Oxifentorex Oxilofrine Ortetamine PBA PCA Phenpromethamine PFA PFMA PIA PMA PMEA PMMA Phenylpropanolamine Pholedrine Prenylamine Propylamphetamine Pseudoephedrine Sibutramine Tiflorex Tranylcypromine Xylopropamine Zylofuramine Entactogens: 4-FA 4-FMA 4-MA 4-MMA 4-MTA 5-APB 5-APDB 5-EAPB 5-IT 5-MAPB 5-MAPDB 6-APB 6-APDB 6-Chloro-MDMA 6-EAPB 6-IT 6-MAPB 6-MAPDB EDA IAP 2,3-MDA 3,4-MDA MDEA MDHMA MDMA MDOH Methamnetamine MMDMA Naphthylaminopropane TAP Others: 3,4-DCA Amiflamine DFMDA Selegiline (also D -Deprenyl)

Phentermines	Stimulants: Chlorphentermine Cloforex Clortermine Etolorex Mephentermine Pentorex Phentermine Entactogens: MDPH MDMPH Others: Cericlamine

Cathinones	Stimulants: 3-FMC 4-MC 4-BMC 4-CMC 4-EMC 4-FMC 4-MEC 4-MeMABP 4-MPD Amfepramone Benzedrone Brephedrone Buphedrone Bupropion Cathinone Dimethylcathinone Ethcathinone Eutylone Hydroxybupropion Methcathinone Methedrone NEB Pentedrone Pentylone Radafaxine Entactogens: 3,4-DMMC 3-MMC Butylone Ethylone Methylone Methylenedioxycathinone Mephedrone

Phenylisobutylamines	Entactogens: 4-CAB 4-MAB Ariadne BDB Butylone EBDB Eutylone MBDB Stimulants: Phenylisobutylamine

Phenylalkylpyrrolidines	Stimulants: α-PBP α-PHP α-PPP α-PVP MDPBP MDPPP MDPV 4-MePBP 4-MePHP 4-MePPP MOPPP MOPVP MPBP MPHP MPPP Naphyrone PEP Prolintane Pyrovalerone

Catecholamines (and close relatives)	6-FNE 6-OHDA a-Me-DA a-Me-TRA Adrenochrome Ciladopa D -DOPA (Dextrodopa) Dimetofrine Dopamine Epinephrine Epinine Etilefrine Ethylnorepinephrine Fenclonine Ibopamine Isoprenaline Isoetarine L -DOPA (Levodopa) L -DOPS (Droxidopa) L -Phenylalanine L -Tyrosine m-Tyramine Metanephrine Metaraminol Metaterol Metirosine Methyldopa N,N-Dimethyldopamine Nordefrin (Levonordefrin) Norepinephrine Norfenefrine (m-Octopamine) Normetanephrine Orciprenaline p-Octopamine p-Tyramine Phenylephrine Synephrine

Miscellaneous	AL-LAD Amidephrine Arbutamine Cafedrine Denopamine Desvenlafaxine Diphenidine Dizocilpine Dobutamine Dopexamine Ephenidine Etafedrine ETH-LAD Famprofazone Fluorolintane Hexapradol IP-LAD Lysergic acid amide Lysergic acid 2-butyl amide Lysergic acid 2,4-dimethylazetidide Lysergic acid diethylamide Methoxamine Methoxphenidine MT-45 PARGY-LAD Phenibut PRO-LAD Pronethalol Salbutamol (Levosalbutamol) Theodrenaline Thiamphenicol UWA-101

匿名

検索

案内

案内